118 related articles for article (PubMed ID: 22964433)
1. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.
Li H; Cai Q; Wu H; Vathipadiekal V; Dobbin ZC; Li T; Hua X; Landen CN; Birrer MJ; Sánchez-Beato M; Zhang R
Mol Cancer Res; 2012 Nov; 10(11):1462-72. PubMed ID: 22964433
[TBL] [Abstract][Full Text] [Related]
2. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
3. Germ cell-specific gene 2 accelerates cell cycle in epithelial ovarian cancer by inhibiting GSK3α-p27 cascade.
Zhu K; Ma X; Guan X; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
J Mol Histol; 2024 Apr; ():. PubMed ID: 38613588
[TBL] [Abstract][Full Text] [Related]
4. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis.
Liu C; Shi X; Wang L; Wu Y; Jin F; Bai C; Song Y
Tumour Biol; 2014 Jun; 35(6):6073-82. PubMed ID: 24633887
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
[TBL] [Abstract][Full Text] [Related]
6. SUZ12 RNA interference inhibits the invasion of gastric carcinoma cells.
Xu XT; Tao ZZ; Song QB; Yao Y; Ruan P
Hepatogastroenterology; 2014; 61(136):2416-20. PubMed ID: 25699394
[TBL] [Abstract][Full Text] [Related]
7. SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin.
Xia R; Jin FY; Lu K; Wan L; Xie M; Xu TP; De W; Wang ZX
Tumour Biol; 2015 Jul; 36(7):5341-51. PubMed ID: 25672609
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.
Zhang M; Wang Y; Jones S; Sausen M; McMahon K; Sharma R; Wang Q; Belzberg AJ; Chaichana K; Gallia GL; Gokaslan ZL; Riggins GJ; Wolinksy JP; Wood LD; Montgomery EA; Hruban RH; Kinzler KW; Papadopoulos N; Vogelstein B; Bettegowda C
Nat Genet; 2014 Nov; 46(11):1170-2. PubMed ID: 25305755
[TBL] [Abstract][Full Text] [Related]
9. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
10. Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Broux M; Prieto C; Demeyer S; Vanden Bempt M; Alberti-Servera L; Lodewijckx I; Vandepoel R; Mentens N; Gielen O; Jacobs K; Geerdens E; Vicente C; de Bock CE; Cools J
Blood; 2019 Oct; 134(16):1323-1336. PubMed ID: 31492675
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.
Xie Z; Cai L; Li R; Zheng J; Wu H; Yang X; Li H; Wang Z
Tumour Biol; 2015 Aug; 36(8):6497-505. PubMed ID: 25833694
[TBL] [Abstract][Full Text] [Related]
12. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.
Lee W; Teckie S; Wiesner T; Ran L; Prieto Granada CN; Lin M; Zhu S; Cao Z; Liang Y; Sboner A; Tap WD; Fletcher JA; Huberman KH; Qin LX; Viale A; Singer S; Zheng D; Berger MF; Chen Y; Antonescu CR; Chi P
Nat Genet; 2014 Nov; 46(11):1227-32. PubMed ID: 25240281
[TBL] [Abstract][Full Text] [Related]
13. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.
De Raedt T; Beert E; Pasmant E; Luscan A; Brems H; Ortonne N; Helin K; Hornick JL; Mautner V; Kehrer-Sawatzki H; Clapp W; Bradner J; Vidaud M; Upadhyaya M; Legius E; Cichowski K
Nature; 2014 Oct; 514(7521):247-51. PubMed ID: 25119042
[TBL] [Abstract][Full Text] [Related]
14. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis.
Peng F; Jiang J; Yu Y; Tian R; Guo X; Li X; Shen M; Xu M; Zhu F; Shi C; Hu J; Wang M; Qin R
Br J Cancer; 2013 Dec; 109(12):3092-104. PubMed ID: 24169343
[TBL] [Abstract][Full Text] [Related]
15. SUZ12 depletion suppresses the proliferation of gastric cancer cells.
Cui Y; Chen J; He Z; Xiao Y
Cell Physiol Biochem; 2013; 31(6):778-84. PubMed ID: 23735840
[TBL] [Abstract][Full Text] [Related]
16. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
17. The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2.
Longhurst AD; Wang K; Suresh HG; Ketavarapu M; Ward HN; Jones IR; Narayan V; Hundley FV; Hassan AZ; Boone C; Myers CL; Shen Y; Ramani V; Andrews BJ; Toczyski DP
bioRxiv; 2024 Mar; ():. PubMed ID: 38562687
[TBL] [Abstract][Full Text] [Related]
18. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
19. PRC2 mediated KLF2 down regulation: a therapeutic and diagnostic axis during tumor progression.
Taghehchian N; Maharati A; Akhlaghipour I; Zangouei AS; Moghbeli M
Cancer Cell Int; 2023 Oct; 23(1):233. PubMed ID: 37807067
[TBL] [Abstract][Full Text] [Related]
20. Functions, mechanisms, and clinical applications of lncRNA LINC00857 in cancer pathogenesis.
Aldayyeni H; Hjazi A; Shahab S; Gupta J; Alsaab HO; Motea YH; Alazbjee AAA; Romero-Parra RM; Obaid RF; Hussien BM; Hosseini-Fard SR
Hum Cell; 2023 Sep; 36(5):1656-1671. PubMed ID: 37378889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
